

## Decreased Incidence of Gout in Diabetic Patients using Pioglitazone.

Niu SW, et al. *Rheumatology (Oxford)*. 2018; 57(1): 92-99.

- The incidence and prevalence of gout are increasing, but the management is poor.
- Considering the increased prevalence of gout in the diabetic population, data from the National Health Insurance program in Taiwan evaluated the effects of pioglitazone, an insulin resistance inhibitor, on the incidence of gout in the diabetic population.
- Incidence of gout was significantly lower in pioglitazone users than in non-pioglitazone users, irrespective of age (Age Groups: <40, 40-59 and  $\geq$ 60 years) and gender.

*Compared with the non-pioglitazone users, the incidence of gout in the diabetic population using pioglitazone was less.*